President Donald Trump’s announcement of a 100% tariff on all branded and patented pharmaceutical imports effective October 1, 2025, has sparked significant concern among Indian drug exporters and global pharmaceutical stakeholders.
Impact on Indian Pharma Sector
India is a major global supplier of pharmaceuticals, exporting over $12 billion worth of medicines to the US, which accounts for more than a third of its total export revenue in this sector. However, most Indian exports to the US are generic drugs, which are not directly affected by these new tariffs. The tariff primarily targets branded and patented drugs—an area where only a select group of Indian companies operate and many already have manufacturing facilities in the US, exempting them from the tariff.
Industry experts remain vigilant over the potential for these tariffs to be extended to more drug categories, including complex generics or biosimilars. Indian pharmaceutical stocks reacted with a 2-3% slide, reflecting market anxiety and uncertainty over future US policy moves.
Broader Economic and Policy Implications
The US government justified the measure as a bid to protect domestic manufacturing and address perceived “flooding” of imported drugs. Tariffs also apply to other goods such as kitchen cabinets and vehicles, but the pharma-specific move is seen as a targeted escalation in President Trump’s broader trade strategy.
Indian companies and government officials are urging for diplomatic interventions and bilateral talks to ensure long-term stability for drug exporters. The Production-Linked Incentive (PLI) scheme, focusing on advancing domestic manufacturing of high-value drugs, has gained new urgency in light of these trade tensions.
US and Global Consequences
American consumers and healthcare providers may see pharmaceutical prices soar if alternative supply lines do not emerge, or if companies cannot quickly set up US-based production units. Global firms from Europe, China, and other Asian nations may also face similar disruptions as the US implements its newest tariff measures.
Indian Pharma’s Response
Key Indian pharma players such as Sun Pharma, Dr Reddy’s, Glenmark, Cipla, and Lupin, which supply patented products to the US, mostly have manufacturing capacities established in America, offering them a buffer against immediate tariff burdens.
Overall, while the bulk of Indian pharma exports may remain shielded for now, sector leaders are keenly watching for any expansion of tariff scope amid broader US-India trade complexities.
